HC Wainwright Has Optimistic Outlook of IPA FY2028 Earnings

Key Points

• HC Wainwright has raised its FY2028 earnings per share (EPS) estimate for ImmunoPrecise Antibodies Ltd. to $0.11, up from $0.08, while maintaining a "Buy" rating and setting a price target of $5.00.
• The company's recent quarterly earnings showed a loss of ($0.04) EPS, missing estimates, with revenue at $5.06 million against expected $7.89 million.
• Institutional ownership of ImmunoPrecise Antibodies is currently at 6.70%, indicating some interest from hedge funds and institutional investors.

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA - Free Report) - Equities researchers at HC Wainwright upped their FY2028 EPS estimates for shares of ImmunoPrecise Antibodies in a note issued to investors on Wednesday, July 30th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of $0.11 for the year, up from their prior forecast of $0.08. HC Wainwright currently has a "Buy" rating and a $5.00 target price on the stock. The consensus estimate for ImmunoPrecise Antibodies' current full-year earnings is ($0.27) per share. HC Wainwright also issued estimates for ImmunoPrecise Antibodies' FY2029 earnings at $0.19 EPS.

Separately, Wall Street Zen upgraded shares of ImmunoPrecise Antibodies from a "sell" rating to a "hold" rating in a research note on Saturday.

ImmunoPrecise Antibodies Stock Down 1.1%

NASDAQ IPA traded down $0.02 during trading hours on Monday, reaching $1.81. The company's stock had a trading volume of 561,332 shares, compared to its average volume of 2,008,765. ImmunoPrecise Antibodies has a fifty-two week low of $0.27 and a fifty-two week high of $2.41. The company's 50-day moving average is $1.25 and its two-hundred day moving average is $0.72. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.08 and a quick ratio of 1.85.

ImmunoPrecise Antibodies (NASDAQ:IPA - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.02). ImmunoPrecise Antibodies had a negative net margin of 122.10% and a negative return on equity of 40.62%. The company had revenue of $5.06 million during the quarter, compared to analyst estimates of $7.89 million.

Institutional Trading of ImmunoPrecise Antibodies

A hedge fund recently raised its stake in ImmunoPrecise Antibodies stock. Ingalls & Snyder LLC boosted its stake in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA - Free Report) by 0.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,779,363 shares of the company's stock after buying an additional 21,236 shares during the quarter. Ingalls & Snyder LLC owned approximately 6.07% of ImmunoPrecise Antibodies worth $2,946,000 as of its most recent SEC filing. 6.70% of the stock is currently owned by hedge funds and other institutional investors.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.